New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 12, 2014
09:25 EDTACOR, ACOR, GENZ, GENZ, NVS, NVS, BIIB, BIIBPiper Jaffray biopharm analyst holds an analyst/industry conference call
Biopharm Analyst Schimmer discusses the current and developing treatment landscape for Multiple Sclerosis including Biogen Idec's Tecfidera, Genzyme's Aubagio, Novartis' Gilenya, Acorda's Ampyra on an Analyst/Industry conference call to be held on June 13 at 9:45 am.
News For ACOR;GENZ;NVS;BIIB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
October 1, 2014
08:07 EDTNVSEnanta regains full rights to EDP-239 for Hep C virus from Novartis
Subscribe for More Information
07:39 EDTBIIBBiogen reinstated with a Neutral at BofA/Merrill
Subscribe for More Information
September 30, 2014
16:39 EDTNVSCMS discloses drug makers' payments to doctors, WSJ says
Subscribe for More Information
07:30 EDTNVSSachs Associates to hold a conference
14th Annual Biotech in Europe Forum for Global Partnering and Investment to be held in Basel, Switzerland on September 30-October 1.
September 29, 2014
09:29 EDTACORAcorda Therapeutics management to meet with JPMorgan
Subscribe for More Information
08:07 EDTNVSPhase 2 trial of binimetinib in NRAS melanoma shows promising clinical activity
Subscribe for More Information
07:26 EDTBIIBInforma Business Information to hold a conference
Subscribe for More Information
September 26, 2014
07:30 EDTNVSNovartis drug Signifor LAR recommended by CHMP for EU approval
The Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or EMA, adopted a positive opinion for Signifor long acting release, or LAR, formulation to treat adult patients with acromegaly for whom surgery is not an option or has not been curative and who are inadequately controlled on treatment with a first-generation somatostatin analogue, or SSA. If approved in the EU, this next-generation SSA could fill a current unmet need, providing a new therapeutic option for the approximately 45% of acromegaly patients whose growth hormone, or GH, or insulin-like growth factor-1, or IGF-1, levels remain inadequately controlled despite treatment with currently available SSAs.
September 25, 2014
05:28 EDTNVSNovartis AIN457 meets primary endpoint in two Phase III studies
Subscribe for More Information
September 24, 2014
16:22 EDTACOROn The Fly: Closing Wrap
Stocks on Wall Street were higher after a report showed that sales of new homes rose to their highest level in over six years in August. The volume and news flow were relatively light, which may be the case again tomorrow as many market participants celebrate the Jewish holiday of Rosh Hashanah. ECONOMIC EVENTS: In the U.S., new home sales rose 18.0% in August to a 504K unit rate, which was much higher than the expected 4.4% increase. COMPANY NEWS: Bed Bath & Beyond (BBBY) advanced $4.64, or 7.4%, to $67.33 after the home goods retailer last night reported second quarter earnings and revenue that surpassed analysts' consensus estimates. The better than expected report and rise in the stock comes a day after William Blair downgraded the stock yesterday morning... Citizen Financial (CFG), the U.S. retail bank unit of Royal Bank of Scotland (RBS), became the year's second largest IPO behind Alibaba (BABA) after 140M shares began trading on the NYSE this morning. The stock ended it first day up $1.58, or 7.35%, at $23.08, which was far cry from the advance seen by another of the day's new stock debuts. CyberArk (CYBR) priced 5.36M shares at $16.00, opened for trade at $25.00 and ended the day at $29.94, making for a rise of over 87% from its IPO pricing. MAJOR MOVERS: Among the notable gainers was Acorda Therapeutics (ACOR), which advanced $8.27, or 28.18%, to $37.62 after the company agreed to acquire Civitas Therapeutics for $525M in cash. Civitas, which was private, had been scheduled to come public via an IPO that was expected to happen later this week prior to the deal announcement. Also higher was Hasbro (HAS), which rose $2.01, or 3.8%, to $54.95 after striking a deal that gives the company global rights, excluding Japan, to develop dolls based on Disney's (DIS) princess characters, as well as Frozen, beginning in 2016. Mattel (MAT), which currently holds those rights, slid 40c, or 1.25%, to $31.67 in the wake of the news. Also lower were shares of Skechers (SKX), which fell $5.69, or 9.8%, to $52.40 after research firm SportscanInfo reported that the footwear maker's sales had fallen 3% last week. However, Sterne Agee recommended buying the stock on the weakness. INDEXES: The Dow rose 154.19, or 0.9%, to 17,210.06, the Nasdaq gained 46.53, or 1.03%, to 4,555.22, and the S&P 500 added 15.53, or 0.78%, to 1,998.30.
13:49 EDTACORAcorda Therapeutics price target raised to $65 from $52 at Cowen
Subscribe for More Information
12:29 EDTACOROn The Fly: Midday Wrap
Subscribe for More Information
10:38 EDTACORAcorda Therapeutics rallies on Civitas Therapeutics acquisition
Subscribe for More Information
09:52 EDTACORAlkermes expects to receive $59M in connection to Acorda-Civitas deal
Subscribe for More Information
09:05 EDTACOROn The Fly: Pre-market Movers
Subscribe for More Information
08:12 EDTACORAcorda Therapeutics to host conference call
Subscribe for More Information
07:27 EDTACORAcorda acquires Civitas Therapeutics for $525M in cash
Subscribe for More Information
07:21 EDTACORAcorda Therapeutics trading halted, pending news
Subscribe for More Information
September 22, 2014
16:07 EDTNVSAnacor announces commercial launch of KERYDIN topical solution in U.S.
Subscribe for More Information
07:21 EDTBIIBEBD Group to hold a conference
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use